The Science Journal of the American Association for Respiratory Care

2012 OPEN FORUM Abstracts


Lisa Tyler1, Leane Soorkian1, Linda Napoli1, James Fink2; 1Respiratory Care, The Children’s Hospital of Philadelphia, Philadelphia, PA; 2Respiratory Therapy, Georgia State University, Atlanta, GA

Background: Delivery of bronchodilators via Aeroneb is common in neonatal mechanically ventilated patients. Using a Dräger ventilator, Neoflow™ sensor placement at the airway is preferred, but impact on aerosol delivery with the sensor in-line has not been reported. Removal of the Neoflow™ sensor to deliver Albuterol to this patient population may lead to increased risk of Ventilator Associated Pneumonia and safety risks related to ventilator setting augmentations. Method: Dräger Evita XL set in PC 20/5 x 30 x 21%, 2.5 mg of albuterol was delivered via Aeroneb Solo placed distal (pre-humidifer) delivered through the inspiratory limb of a neonatal heated wire circuit (37 ± 1° C) with and without the Neoflow™ sensor. Drug was collected on a nonconductive respiratory filter distal to a 3.5 mm ETT, and attached to a passive test lung. The same circuit was used for all trials (n=3); they were performed in the order listed. Samples were eluted from the filters using an ethanol/water mixture. Absorbance at 276 nm was used to estimate the amount of albuterol in the eluent. Results: Table belowshows results of each run with ug of albuterol also expressed as mean ± SD. Conclusion: Despite a trend toward higher drug delivery with Neoflow removed, T test showed no statistical difference in the deposition with the Neoflow™ sensor present or absent from the circuit. Further studies are needed to standardize delivery method and quantify dose delivered with and without Neoflow.™ Sponsored Research - None Comparison of Drug Delivery With and Without Neoflow™